Cardiff Oncology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRDF Nasdaq 2834 www.cardiffoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cardiff Oncology, Inc.

Cardiff Oncology to share CRDF-004 trial data on July 29 - Jun 19th, 2025 7:25 am
Cardiff selloff brings attractive entry point, says H.C. Wainwright - Jun 19th, 2025 7:25 am
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC - Jun 17th, 2025 2:05 pm
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - Jun 2nd, 2025 2:05 pm
Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - May 10th, 2025 6:13 am
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - May 8th, 2025 2:05 pm
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - Apr 23rd, 2025 2:05 pm
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 15th, 2025 2:10 pm
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - Apr 15th, 2025 2:05 pm
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Mar 1st, 2025 6:17 am
Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Feb 27th, 2025 2:05 pm
Cardiff Oncology to Present at Upcoming Investor Conferences - Feb 24th, 2025 2:05 pm
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update - Feb 20th, 2025 2:05 pm
Bullish Cardiff Oncology Insiders Rewarded As Their Investment Rises To US$1.81m - Feb 20th, 2025 4:51 am
While institutions own 25% of Cardiff Oncology, Inc. (NASDAQ:CRDF), retail investors are its largest shareholders with 57% ownership - Dec 23rd, 2024 6:13 am
Cardiff Oncology price target raised to $10 from $7 at Piper Sandler - Dec 14th, 2024 4:50 am
Cardiff Oncology Reports Promising Phase 2 Trial Results - Dec 11th, 2024 5:19 am
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering - Dec 10th, 2024 5:20 am
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial - Dec 10th, 2024 4:00 am
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC - Nov 19th, 2024 6:00 am